Maxiphoto/iStock via Getty Images Alimera Sciences ( NASDAQ: ALIM ) soared 75% in premarket trade, after ANI Pharmaceuticals ( NASDAQ: ANIP ) said it will acquire the firm for $5.50 per share in cash at closing. The $5.
50 per share is at a premium of 74.6% from the last close on Friday. The deal, which values ALIM at $381M in up front consideration, also includes a one non-tradable contingent value right representing the right to receive up to $0.
50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANIP said the acquisition will further boost its rare disease business, and also expects the deal to generate high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial accretion thereafter. The deal is anticipated to deliver additional $35M - $38M in 2025 adjusted non-GAAP core profit, inclusive of ~$10 million in identified cost synergies.
ANIP intends to finance the transaction using a combination of cash on hand and debt financing. Shares in ANIP were down 1.5% in premarket trade.
More on ANI Pharmaceuticals ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked ANI Pharmaceuticals, Inc. (ANIP) Q1 2024 Earnings Call Transcript ANI Pharmaceuticals Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on ANI Pharmaceuticals Historical earnings data for ANI Pharmaceuticals.
